An Acadia Pharmaceuticals Insider Sold Nearly Half Their Shares in the Company. What Does That Mean for Investors?

Transaction summary

Transaction worth based connected SEC Form 4 weighted mean terms ($26.08); post-transaction worth based connected June 26, 2026 marketplace adjacent price.

Key questions

• How does this transaction comparison to anterior open-market income by James Kihara?
  This 11,421-share merchantability is Kihara's largest azygous open-market merchantability connected record, exceeding his erstwhile merchantability connected May 26, 2026 (5,401 shares), and surpassing the five-trade mean of astir 4,964 shares per sale.

• What proportionality of Kihara's disposable nonstop shareholding was progressive successful this sale?
  The transaction represented 46.60% of his nonstop holdings anterior to the sale, a important simplification that near lone 13,088 shares straight held post-transaction.

• Were immoderate derivative oregon indirect holdings progressive successful this disposition?
  No derivative securities oregon indirect entities were involved; each shares sold were straight owned communal stock, and nary options oregon trust-held shares were reported successful this filing.

• Does the cadence oregon standard of this merchantability bespeak a alteration successful disposition strategy?
  Recent filings bespeak an acceleration successful selling arsenic Kihara's holdings person declined, with expanding merchantability sizes explained by the drawdown successful disposable capableness alternatively than a discretionary slow-down oregon escalation.

Company overview

*1-year terms alteration calculated arsenic of June 26, 2026.

Company snapshot

• Core product: NUPLAZID (pimavanserin) for Parkinson's illness psychosis; pipeline includes late-stage candidates for Alzheimer's illness psychosis, Rett syndrome, and symptom management.

• Revenue is chiefly generated done the commercialization of proprietary therapeutics for cardinal tense strategy (CNS) disorders, with further maturation imaginable from clinical-stage assets.

• Target customers see neurologists, psychiatrists, and healthcare providers treating CNS disorders, with a absorption connected patients experiencing unmet aesculapian needs.

Acadia Pharmaceuticals is simply a biopharmaceutical institution specializing successful the discovery, development, and commercialization of innovative treatments for cardinal tense strategy disorders.